OPEN ACCESS Freely available online

Acute and Chronic Disease Reports

Perspective

Advanced Targeted Therapies for Acute Leukemia: Progress and Prospects

Eric Topol*

Department of Medicine, Scripps Research Translational Institute, California, USA

DESCRIPTION

Acute leukemia, a swift-progressing cancer of blood and bone marrow, has long posed treatment challenges due to its aggressive nature and molecular diversity. Traditional treatments, such as chemotherapy and stem cell transplantation, have been critical but are often associated with significant side effects and limited efficacy, particularly for patients with relapsed or refractory disease. However, advances in the understanding of the molecular and genetic bases of acute leukemia have led to the development of targeted therapies, designed to selectively attack leukemia cells while minimizing harm to healthy cells. This new approach promises better outcomes with fewer side effects, reshaping the landscape of acute leukemia treatment.

Current status of targeted therapies in acute leukemia

Recent years have seen remarkable progress in targeted therapies for acute leukemia, with several key treatments now available. These therapies are particularly effective for specific genetic mutations found in two main types of acute leukemia-Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL).

Isocitrate Dehydrogenase 1(IDH1) and Isocitrate Dehydrogenase 2(IDH2) Inhibitors: Mutations in the IDH1 and IDH2 genes, present in about 20% of AML cases, contribute to abnormal cell growth and leukemia progression. Ivosidenib Isocitrate Dehydrogenase 1 inhibitor (IDH1) inhibitor and Enasidenib Isocitrate Dehydrogenase 2 inhibitor (IDH2) inhibitor have shown efficacy in patients with relapsed or refractory AML, providing promising alternatives to traditional therapies. These drugs have demonstrated significant response rates, validating the role of targeting metabolic pathways in leukemia treatment.

B-Cell Lymphoma 2 (BCL-2) inhibitor: Venetoclax, a B-Cell Lymphoma 2 (BCL-2) inhibitor, has transformed AML treatment, particularly for older patients who cannot tolerate intensive chemotherapy. By blocking the BCL-2 protein, which helps leukemia cells avoid apoptosis, venetoclax promotes cancer cell death. Used in combination with hypomethylating agents, venetoclax has led to high response rates and longer survival, representing a key advance for AML patients.

Combination therapies: Combining targeted therapies with each other or with standard treatments, like chemotherapy, may enhance effectiveness and reduce resistance. For instance, combining FLT3 inhibitors with other targeted or immune therapies is being explored for AML. In ALL, combining Chimeric Antigen Receptor T (CART) therapy with checkpoint inhibitors may sustain remissions by enhancing immune response.

Next-generation targeted Agents: Resistance to first-generation inhibitors is a common obstacle, often arising from secondary mutations or alternative signaling pathways that leukemia cells adopt. Consequently, second- and third-generation agents are being developed to more effectively block these escape routes. Newer FLT3 inhibitors, for example, bind more specifically to the mutated FLT3 receptors, aiming to improve effectiveness and reduce side effects.

CONCLUSION

Targeted therapies have brought new hope to patients with acute leukemia, offering more effective and less toxic alternatives to traditional treatments. By focusing on the specific genetic and molecular drivers of leukemia, these therapies are reshaping the treatment paradigm. Future advancements, especially in combination approaches, next-generation agents, and precision medicine, promise to push the boundaries of acute leukemia treatment even further. While challenges like drug resistance and high costs remain, ongoing studies and innovation are paving the way for a future in which acute leukemia may be more effectively managed and, potentially, cured. As this approach evolves, clinicians may soon be able to adapt treatment plans in real-time based on patients' genetic profiles and responses to treatment.

Correspondence to: Eric Topol, Department of Medicine, Scripps Research Translational Institute, California, USA, E-mail: etopol@scripps.edu

Received: 21-Aug-2024, Manuscript No. ACDR-24-35056; **Editor assigned:** 23-Aug-2024, PreQC No. ACDR-24-35056 (PQ); **Reviewed:** 06-Sep-2024, QC No. ACDR-24-35056; **Revised:** 16-Sep-2024, Manuscript No. ACDR-24-35056 (R); **Published:** 23-Sep-2024, DOI: 10.35248/ACDR. 24.8.226

Citation: Topol E (2024).Advanced Targeted Therapies for Acute Leukemia: Progress and Prospects. Acute Chronic Dis. 8:226.